Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2Unknown 1Terminated 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 330Thoracic 169CNS 139Breast 129Gynecologic 104Genitourinary 71Sarcoma 55Tumor-Agnostic 37Dermatologic 29Other solid neoplasm 27Head & Neck 18Lymphoid 16Other hematologic neoplasm 13Endocrine 9Plasma cell 6Myeloid 4Classical hematology 3NET 2

Conditions

Neuroendocrine Tumors 2

Interventions

Everolimus 19lutetium Lu 177 dotatate 8Octreotide 8lanreotide 7pasireotide 6Temozolomide 6Sunitinib 6pembrolizumab 5gallium Ga 68 dotatate 5Positron Emission Tomography Computed Tomography 5surufatinib 4Sorafenib 4Data Collection 4Carboplatin 43-Iodobenzylguanidine 4Positron-Emission Tomography 3Nivolumab 3Magnetic Resonance Spectroscopy 3Etoposide 3Capecitabine 390Y-octreotide, DOTA-Tyr(3)- 3pentetreotide 2pazopanib 2lenvatinib 2fosbretabulin 2fluorodopa F 18 2cabozantinib 2avelumab 2arginyllysine 2Single Photon Emission Computed Tomography Computed Tomography 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Bevacizumab × NET × Clear all
NCT00398320 2017-03-01

Phase II Capecitabine, Oxaliplatin & Bevacizumab for Metastatic / Unresectable Neuroendocrine Tumors

Stanford University

Phase 2 Completed
40 enrolled 9 charts
EndocrineNET

Neuroendocrine Tumors

NCT00137774 2013-04-09

Bevacizumab in Combination With Temozolomide in Patients With Neuroendocrine Tumors

Dana-Farber Cancer Institute

Phase 2 Completed
34 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡